Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 11:8:48.
doi: 10.3389/fcell.2020.00048. eCollection 2020.

A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants

Affiliations
Review

A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants

Xuanyi Li et al. Front Cell Dev Biol. .

Abstract

The increased availability of tumor genetic testing and targeted cancer therapies contributes to the advancement of precision medicine in the field of oncology. Precision oncology knowledgebases provide a way of organizing clinically relevant genetic information in a way that is easily accessible for both oncologists and patients, facilitating the genetic-based clinical decision making. Many organizations and companies have built precision oncology knowledgebases, intended for multiple users. In general, these knowledgebases offer information on cancer-related genetic variants as well as their associated diagnostic, prognostic, and therapeutic implications, but they often differ in their information curations, designs, and user experiences. It is advisable that oncologists use multiple knowledgebases during their practice to have them complement each other. In the future, convergence toward common standards and formats is needed to ensure that the comprehensive knowledge across all sources can be unified to bring the oncology community closer to the achievement of the goal of precision oncology.

Keywords: actionability; genotype-selective clinical trial; knowledgebase; precision oncology; targeted therapy; tumor genetic testing; variant interpretation.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
NGS workflow. The processes of ordering, measuring, interpreting, and acting upon clinical NGS information are complex and shared across clinician specialties. This schema outlines the tasks in the typical workflow of precision oncology decision making. Notably this process is iterative, with repetition typically triggered by progression or a prespecified time interval. The brackets illustrate the portion of the workflow that is the subject of this focused review. Traditionally, the test ordering and interpretation steps have clear hand-offs, although roles are becoming increasingly shared e.g., with the advent of molecular tumor boards. While the discussed knowledgebases may have purposes outside of this narrow scope, they also have clear utility in this part of the workflow. Conversely, resources such as COSMIC and dbSNP, which are useful for the laboratory professionals and pathologists’ role in interpreting sequencing data and annotating variants, are deliberately omitted in this mini-review, as they do not typically have a role in this portion of the workflow.

References

    1. AACR Project Genie Consortium (2017). AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7 818–831. 10.1158/2159-8290.CD-17-0151 - DOI - PMC - PubMed
    1. Andre F., Mardis E., Salm M., Soria J. C., Siu L. L., Swanton C. (2014). Prioritizing targets for precision cancer medicine. Ann. Oncol. 25 2295–2303. 10.1093/annonc/mdu478 - DOI - PubMed
    1. Bailey M. H., Tokheim C., Porta-Pardo E., Sengupta S., Bertrand D., Weerasinghe A., et al. (2018). Comprehensive characterization of cancer driver genes and mutations. Cell 173 371–385. 10.1016/j.cell.2018.02.060 - DOI - PMC - PubMed
    1. Bates D. W., Kuperman G. J., Wang S., Gandhi T., Kittler A., Volk L., et al. (2003). Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J. Am. Med. Inform. Assoc. 10 523–530. 10.1197/jamia.M1370 - DOI - PMC - PubMed
    1. Bertrand D., Drissler S., Chia B. K., Koh J. Y., Li C., Suphavilai C., et al. (2018). ConsensusDriver improves upon individual algorithms for predicting driver alterations in different cancer types and individual patients. Cancer Res. 78 290–301. 10.1158/0008-5472.CAN-17-1345 - DOI - PubMed

LinkOut - more resources